Natco Pharma Ltd Financials
Company Logo

Natco Pharma Ltd Financial Statement

Natco Pharma Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Mar 2025
Revenue1219.50
Operating Expense596.20
Net Profit428.10
Net Profit Margin35.10
Earning Per Share23.90
EBIDTA630.00
Effective Tax Rate15.95

Natco Pharma Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual3,568.90
Operating Expenses Annual1,931.90
Operating Profit Annual1,741.70
Interest Annual14.50
Depreciation171.90
Net Profit Annual1,306.60
Tax Annual248.70

Natco Pharma Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning6.90
Cash Flow from Operations1,196.40
Cash Flow from Investing-960.50
Cash Flow from Financing-237.30
Cash Flow at the End5.50

Natco Pharma Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)48.80
PBIT Margin (%)43.99
PBT Margin (%)40.96
Net PROFIT Margin (%)36.61
Return On Networth / Equity (%)25.38
Return On Networth /Employed (%)28.58
Return On Assets (%)23.80
Total Debt / Equity (X)0.05
Asset Turnover Ratio (%)0.65

Natco Pharma Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual2,286.70
Total Current Assets Annual3,410.40
Non Current Assets Annual3,143.60
Total Shareholders Funds Annual5,592.30
Total Assets Annual6,554

Natco Pharma Ltd Earning Calls

EPS (INR)

Expected

22.72

Reported

22.70

Surprise

-0.09%

Dec 2024

EPS beaten by -0.09%

Sep 2024

EPS beaten by 0.00%

Jun 2024

EPS beaten by -0.08%

FAQS on Natco Pharma Ltd Financials

As of Jun 6, 2025, Natco Pharma Ltd has a market capitalization of 14,287.59 Cr. Value Research classifies it as a Large-Cap company.

Yes, Natco Pharma Ltd is with a debt-to-equity ratio of 0.04.

In FY 2024 , Natco Pharma Ltd recorded a total revenue of approximately 4,094.50 Cr marking a significant milestone in the company's financial performance.

Natco Pharma Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.2% and 0.3% annually, respectively..

Natco Pharma Ltd's current PE ratio is 7.72.

Natco Pharma Ltd's ROCE averaged 23.9% from the FY ending March 2023 to 2025, with a median of 26.3%. It peaked at 29.5% in March 2025, reflecting strong capital efficiency over the period..

Natco Pharma Ltd's latest EBIT is Rs. 2,245.60 Cr, surpassing the average EBIT of Rs. 1,531.57 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions